

Osamu Matsuo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7088103/publications.pdf>

Version: 2024-02-01

147
papers

2,783
citations

218677

26
h-index

233421

45
g-index

149
all docs

149
docs citations

149
times ranked

3020
citing authors

#	ARTICLE	IF	CITATIONS
1	Stabilization of plasmin by lysine derivatives. <i>Clinica Chimica Acta</i> , 1996, 245, 7-18.	1.1	267
2	VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. <i>Journal of Clinical Investigation</i> , 2008, 118, 913-23.	8.2	144
3	Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: Impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. <i>Hepatology</i> , 2001, 33, 569-576.	7.3	100
4	Loss of placental growth factor protects mice against vascular permeability in pathological conditions. <i>Biochemical and Biophysical Research Communications</i> , 2002, 295, 428-434.	2.1	81
5	Mesenchymal progenitor cells in adult human dental pulp and their ability to form bone when transplanted into immunocompromised mice. <i>Cell Biology International</i> , 2007, 31, 1191-1197.	3.0	81
6	Differential Role of Components of the Fibrinolytic System in the Formation and Removal of Thrombus Induced by Endothelial Injury. <i>Thrombosis and Haemostasis</i> , 1999, 81, 601-604.	3.4	64
7	Plasminogen Plays a Crucial Role in Bone Repair. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1561-1574.	2.8	62
8	Mechanism of fibrin-specific fibrinolysis by staphylokinase: Participation of \pm 2-plasmin inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 1989, 162, 830-837.	2.1	57
9	Role of Plasminogen Activator Inhibitor-1 in Glucocorticoid-Induced Diabetes and Osteopenia in Mice. <i>Diabetes</i> , 2015, 64, 2194-2206.	0.6	55
10	On the molecular interactions between plasminogen-staphylokinase, \pm 2-antiplasmin-formula> and fibrin. <i>BBA - Proteins and Proteomics</i> , 1992, 1118, 144-148.	2.1	49
11	Plasminogen Activator Inhibitor-1 Is Involved in Streptozotocin-Induced Bone Loss in Female Mice. <i>Diabetes</i> , 2013, 62, 3170-3179.	0.6	46
12	Plasminogen Activator Inhibitor-1 Is Involved in Impaired Bone Repair Associated with Diabetes in Female Mice. <i>PLoS ONE</i> , 2014, 9, e92686.	2.5	46
13	Plasminogen/Plasmin Modulates Bone Metabolism by Regulating the Osteoblast and Osteoclast Function. <i>Journal of Biological Chemistry</i> , 2011, 286, 8952-8960.	3.4	45
14	The Absence of uPAR Is Associated with the Progression of Dermal Fibrosis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2792-2797.	0.7	44
15	Protection of Plasminogen Activator Inhibitor-1-Deficient Mice from Nasal Allergy. <i>Journal of Immunology</i> , 2005, 174, 8135-8143.	0.8	43
16	A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 935-942.	2.4	43
17	Grafting of vinyl monomers on the surface of a poly(ethylene terephthalate) film using Ar plasma-post polymerization technique to increase biocompatibility. <i>Macromolecular Chemistry and Physics</i> , 1998, 199, 1201-1208.	2.2	42
18	uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca ²⁺ /CaMKK/AMPK Axis. <i>International Journal of Biological Sciences</i> , 2016, 12, 63-71.	6.4	41

#	ARTICLE	IF	CITATIONS
19	Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. <i>Thrombosis Research</i> , 1988, 52, 165-171.	1.7	40
20	Lack of α 2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. <i>Blood</i> , 2002, 100, 2487-2493.	1.4	39
21	Plasminogen activator inhibitor 1 in human carcinoma tissues. <i>International Journal of Cancer</i> , 1991, 48, 481-484.	5.1	35
22	The regulation of liver regeneration by the plasmin/ α 2-antiplasmin system. <i>Journal of Hepatology</i> , 2004, 40, 110-116.	3.7	31
23	Tissue Type Plasminogen Activator Facilitates NMDA-Receptor-Mediated Retinal Apoptosis through an Independent Fibrinolytic Cascade. , 2005, 46, 1504.		31
24	α 2-Antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F ₂ synthesis through adipose triglyceride lipase/calcium-independent phospholipase A ₂ . <i>Arthritis and Rheumatism</i> , 2013, 65, 492-502.	6.7	31
25	Tissue-type plasminogen activator deficiency delays bone repair: roles of osteoblastic proliferation and vascular endothelial growth factor. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 307, E278-E288.	3.5	31
26	Tissue plasminogen activator and plasminogen are critical for osmotic homeostasis by regulating vasopressin secretion. <i>Journal of Neuroscience Research</i> , 2010, 88, 1995-2006.	2.9	30
27	Plasminogen Activator Inhibitor-1 Deficiency Ameliorates Insulin Resistance and Hyperlipidemia But Not Bone Loss in Obese Female Mice. <i>Endocrinology</i> , 2014, 155, 1708-1717.	2.8	29
28	Systemic transplantation of embryonic stem cells accelerates brain lesion decrease and angiogenesis. <i>NeuroReport</i> , 2010, 21, 575-579.	1.2	26
29	Plasmin Generation Plays different Roles in the Formation and Removal of Arterial and Venous Thrombus in Mice. <i>Thrombosis and Haemostasis</i> , 2002, 87, 98-104.	3.4	25
30	Development of New Fibrinolytic Agents. <i>Current Pharmaceutical Design</i> , 2006, 12, 849-857.	1.9	25
31	Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke. <i>Neuroscience Letters</i> , 2008, 432, 46-49.	2.1	25
32	α 2-Antiplasmin Is Associated with the Progression of Fibrosis. <i>American Journal of Pathology</i> , 2010, 176, 238-245.	3.8	25
33	Localization of plasminogen in mouse hippocampus, cerebral cortex, and hypothalamus. <i>Cell and Tissue Research</i> , 2011, 343, 303-317.	2.9	25
34	Involvement of α 2-Antiplasmin in dendritic growth of hippocampal neurons. <i>Journal of Neurochemistry</i> , 2013, 126, 58-69.	3.9	25
35	Biocompatible Block Copolymers Composed of Polydimethylsiloxane and Poly[(2-methacryloyloxy)ethyl phosphorylcholine] Segments. <i>Polymer Journal</i> , 1999, 31, 883-886.	2.7	23
36	α 2-Antiplasmin Is a Critical Regulator of Angiotensin II-Mediated Vascular Remodeling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1257-1262.	2.4	22

#	ARTICLE	IF	CITATIONS
37	In Vivo Diagnostic Imaging Using Micro-CT: Sequential and Comparative Evaluation of Rodent Models for Hepatic/Brain Ischemia and Stroke. PLoS ONE, 2012, 7, e32342.	2.5	22
38	The Tissue Fibrinolytic System Contributes to the Induction of Macrophage Function and CCL3 during Bone Repair in Mice. PLoS ONE, 2015, 10, e0123982.	2.5	22
39	Roles of urokinase type plasminogen activator in a brain stab wound. Brain Research, 2000, 887, 187-190.	2.2	21
40	The Role of the Pericellular Fibrinolytic System in Angiogenesis.. The Japanese Journal of Physiology, 1997, 47, 161-171.	0.9	20
41	Urokinase-type plasminogen activator receptor is associated with the development of adipose tissue. Thrombosis and Haemostasis, 2010, 104, 1124-1132.	3.4	20
42	Analysis of binding protein for tissue-type plasminogen activator in human endothelial cells. Biochemical and Biophysical Research Communications, 1992, 187, 956-962.	2.1	19
43	Initial brain lesion size affects the extent of subsequent pathophysiological responses. Brain Research, 2010, 1322, 109-117.	2.2	19
44	Î±2AP mediated myofibroblast formation and the development of renal fibrosis in unilateral ureteral obstruction. Scientific Reports, 2014, 4, 5967.	3.3	19
45	Enhancement of tissue-type plasminogen activator (t-PA) activity by purified t-PA receptor expressed in human endothelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1356, 111-120.	4.1	18
46	Lack of Î±2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice. Blood, 2003, 102, 3621-3628.	1.4	18
47	Role of plasminogen activator inhibitor-1 in glucocorticoid-induced muscle change in mice. Journal of Bone and Mineral Metabolism, 2018, 36, 148-156.	2.7	18
48	Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines. Clinica Chimica Acta, 2000, 296, 17-33.	1.1	17
49	c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells. Cardiovascular Research, 2007, 75, 186-194.	3.8	17
50	The Roles of Urokinase-Type Plasminogen Activator in Leukocyte Infiltration and Inflammatory Responses in Mice Corneas Treated With Lipopolysaccharide. , 2014, 55, 5338.		17
51	Plasminogen activator inhibitorâ€1 deficiency suppresses osteoblastic differentiation of mesenchymal stem cells in mice. Journal of Cellular Physiology, 2019, 234, 9687-9697.	4.1	17
52	Monoclonal antibody to human tissue plasminogen activator. Thrombosis Research, 1984, 36, 517-526.	1.7	16
53	Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. Journal of Pathology, 1992, 166, 289-295.	4.5	16
54	Urokinase-type plasminogen activator and plasminogen mediate activation of macrophage phagocytosis during liver repair in vivo. Thrombosis and Haemostasis, 2012, 107, 749-759.	3.4	16

#	ARTICLE	IF	CITATIONS
55	Altered Behavior in Mice with Deletion of the Alpha2-Antiplasmin Gene. PLoS ONE, 2014, 9, e97947.	2.5	16
56	Effects of fibrin and α_2 -antiplasmin on plasminogen activation by staphylokinase. , 1996, 53, 151-157.		15
57	Role of plasminogen in macrophage accumulation during liver repair. Thrombosis Research, 2010, 125, e214-e221.	1.7	15
58	Urokinase-type plasminogen activator contributes to heterogeneity of macrophages at the border of damaged site during liver repair in mice. Thrombosis and Haemostasis, 2011, 105, 892-900.	3.4	15
59	α_2 -Antiplasmin is involved in bone loss induced by ovariectomy in mice. Bone, 2015, 79, 233-241.	2.9	15
60	The blocking of uPAR suppresses lipopolysaccharide-induced inflammatory osteoclastogenesis and the resultant bone loss through attenuation of integrin β_3 /Akt pathway. Immunity, Inflammation and Disease, 2016, 4, 338-349.	2.7	15
61	Role of Macrophages and Plasminogen Activator Inhibitor-1 in Delayed Bone Repair in Diabetic Female Mice. Endocrinology, 2018, 159, 1875-1885.	2.8	15
62	Inhibitors of Fibrinolytic Components Play Different Roles in the Formation and Removal of Arterial Thrombus in Mice. Journal of Cardiovascular Pharmacology, 2002, 39, 278-286.	1.9	14
63	Endogenous tissue type plasminogen activator facilitates NMDA-induced retinal damage. Toxicology and Applied Pharmacology, 2004, 200, 48-53.	2.8	14
64	Unbalanced expression of ADAMTS13 and von Willebrand factor in mouse endotoxemia. Thrombosis Research, 2008, 122, 91-97.	1.7	14
65	The absence of uPAR attenuates insulin-induced vascular smooth muscle cell migration and proliferation. Thrombosis Research, 2008, 123, 336-341.	1.7	14
66	α_2 AP is associated with the development of lupus nephritis through the regulation of plasmin inhibition and inflammatory responses. Immunity, Inflammation and Disease, 2020, 8, 267-278.	2.7	14
67	Antithrombotic Regulation in Human Endothelial Cells by Fibrinolytic Factors. Seminars in Thrombosis and Hemostasis, 2000, Volume 26, 033-038.	2.7	14
68	Production and characterization of single-chain tissue-type plasminogen activator produced by an established cell line from human uterine muscle.. Cell Structure and Function, 1989, 14, 45-60.	1.1	14
69	High-performance chromatographic method for the purification of tissue-type plasminogen activator. Journal of Chromatography A, 1986, 369, 391-397.	3.7	13
70	Effects of lipopolysaccharide on the expression of fibrinolytic factors in an established cell line from human endothelial cells. Life Sciences, 1996, 59, 85-96.	4.3	13
71	Function of Tissue-type Plasminogen Activator Releaser on Vascular Endothelial Cells and Thrombolysis In Vivo. Thrombosis and Haemostasis, 2002, 87, 1069-1074.	3.4	13
72	Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice. Thrombosis and Haemostasis, 2002, 87, 98-104.	3.4	13

#	ARTICLE	IF	CITATIONS
73	Characterization of plasminogen activator produced by an established cell line from human ovary. <i>Journal of Cellular Physiology</i> , 1988, 134, 253-260.	4.1	12
74	Plasminogen Activator Inhibitor in Stomach and Colorectal Carcinomas. <i>Seminars in Thrombosis and Hemostasis</i> , 1991, 17, 276-279.	2.7	12
75	Lack of tPA Significantly Affects Antithrombotic Therapy by a GPIIb/IIIa Antagonist, but not by a Thrombin Inhibitor in Mice. <i>Thrombosis and Haemostasis</i> , 2000, 83, 605-609.	3.4	12
76	Plasminogen activator inhibitor-1 deficiency enhances subchondral osteopenia after induction of osteoarthritis in mice. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 392.	1.9	12
77	Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. <i>Thrombosis and Haemostasis</i> , 2003, 89, 820-825.	3.4	11
78	Plasmin decreases the BH3-only protein BimEL via the ERK1/2 signaling pathway in hepatocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 718-727.	4.1	11
79	PAI-1 is involved in delayed bone repair induced by glucocorticoids in mice. <i>Bone</i> , 2020, 134, 115310.	2.9	11
80	Transcriptional Regulation of Urokinase-type Plasminogen Activator Receptor by Cyclic AMP in PL-21 Human Myeloid Leukemia Cells: Comparison with the Regulation by Phorbol Myristate Acetate. <i>Thrombosis and Haemostasis</i> , 1998, 79, 574-578.	3.4	10
81	Effect of Heat Shock on the Expression of Urokinase-Type Plasminogen Activator Receptor in Human Umbilical Vein Endothelial Cells. <i>Thrombosis and Haemostasis</i> , 1996, 75, 352-358.	3.4	10
82	Activity of tissue plasminogen activator and plasminogen activator inhibitor in noninsulin-dependent diabetes mellitus. <i>The Journal of Diabetic Complications</i> , 1990, 4, 119-121.	0.2	9
83	Surface Modified Poly(methyl methacrylate) Microspheres with the O-Methacryloyl-L-serine Moiety. <i>Chemistry Letters</i> , 1997, 26, 863-864.	1.3	9
84	Suppression of the release of type-1 plasminogen activator inhibitor from human vascular endothelial cells by Hawaii deep sea water. <i>Pathophysiology</i> , 2003, 9, 103-109.	2.2	9
85	Lack of both α 2-antiplasmin and plasminogen activator inhibitor type-1 induces high IgE production. <i>Life Sciences</i> , 2013, 93, 89-95.	4.3	9
86	Tissue plasminogen activator modulates emotion in a social context. <i>Behavioural Brain Research</i> , 2015, 281, 24-31.	2.2	9
87	Effect of bone resorbing factors on u-PA and its specific receptor in osteosarcoma cell line. <i>Clinica Chimica Acta</i> , 1993, 223, 129-142.	1.1	8
88	Effect of cyclic AMP on urokinase-type plasminogen activator receptor and fibrinolytic factors in a human osteoblast-like cell line. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1995, 1266, 50-56.	4.1	8
89	Lack of α 2-antiplasmin enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice. <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 205-211.	2.1	8
90	Binding of plasminogen to hepatocytes isolated from injured mice liver and nonparenchymal cell-dependent proliferation of hepatocytes. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 503-511.	1.0	8

#	ARTICLE	IF	CITATIONS
91	Involvement of Plasminogen Activator Inhibitor-1 in the Pathogenesis of Atopic Cataracts. , 2012, 53, 1846.		8
92	Plasminogen deficiency is associated with improved glucose tolerance, and lower DPP-4 activity. Diabetes Research and Clinical Practice, 2016, 120, 190-193.	2.8	8
93	Î±2-antiplasmin modulates bone formation by negatively regulating osteoblast differentiation and function. International Journal of Molecular Medicine, 2017, 40, 854-858.	4.0	8
94	tPA, but not uPA, Significantly Affects Antithrombotic Therapy by a Glycoprotein IIb/IIIa Antagonist, but not by a Factor Xa Inhibitor. Journal of Cardiovascular Pharmacology, 2000, 36, 770-775.	1.9	8
95	Î±2-antiplasmin positively regulates endothelial-to-mesenchymal transition and fibrosis progression in diabetic nephropathy. Molecular Biology Reports, 2022, 49, 205-215.	2.3	8
96	Trial of integrated laboratory practice. American Journal of Physiology - Advances in Physiology Education, 2011, 35, 237-240.	1.6	7
97	Evaluation of antithrombotic effect: Importance of testing components and methodologies. Drug Discoveries and Therapeutics, 2015, 9, 258-266.	1.5	7
98	Association of Nonalcoholic Fatty Liver Disease and Venous Thromboembolism in Women With Endometrial Cancer. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 1018-1027.	1.7	7
99	Identification of Urokinase-type Plasminogen Activator Receptor in Human Endothelial Cells and its Modulation by Phorbol Myristate Acetate.. Cell Structure and Function, 1995, 20, 429-437.	1.1	7
100	Analysis of Tissue-Type Plasminogen Activator Receptor (t-PAR) in Human Endothelial Cells. Seminars in Thrombosis and Hemostasis, 1998, 24, 269-273.	2.7	6
101	Cellular density regulation of plasminogen gene expression in mouse hepatocytes. Life Sciences, 2003, 72, 1695-1704.	4.3	6
102	Effect of staphylokinase-derived nonadecapeptide on the activation of plasminogen. Thrombosis and Haemostasis, 2007, 97, 795-802.	3.4	6
103	Profibrinolytic effect of Enzamin, an extract of metabolic products from Bacillus subtilis AK and Lactobacillus. Journal of Thrombosis and Thrombolysis, 2011, 32, 195-200.	2.1	6
104	Enhanced urokinase-type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line. Clinica Chimica Acta, 1996, 253, 37-50.	1.1	5
105	Determination of a factor VIII-interactive region within plasmin responsible for plasmin-catalysed activation and inactivation of factor VIII(a). Thrombosis and Haemostasis, 2010, 104, 105-117.	3.4	5
106	Roles of fibrinolytic system components in the nervous system. Pathophysiology, 2010, 17, 141-147.	2.2	5
107	Co-localization of Urokinase and its Receptor on Established Human Umbilical Vein Endothelial Cell.. Cell Structure and Function, 1999, 24, 71-78.	1.1	5
108	Nigral degeneration following striato-pallidal lesion in tissue type plasminogen activator deficient mice. Neuroscience Letters, 1999, 266, 220-222.	2.1	4

#	ARTICLE	IF	CITATIONS
109	The interaction between components of the fibrinolytic system and GPIb/IX of platelets thrombus formation in mice. <i>British Journal of Pharmacology</i> , 2000, 131, 858-864.	5.4	4
110	Enzamin ameliorates adipose tissue inflammation with impaired adipocytokine expression and insulin resistance in db/db mice. <i>Journal of Nutritional Science</i> , 2013, 2, e37.	1.9	4
111	Roles of plasminogen in the alterations in bone marrow hematopoietic stem cells during bone repair. <i>Bone Reports</i> , 2018, 8, 195-203.	0.4	4
112	Short-term inhibition of fibrinolytic system restores locomotor function after spinal cord injury in mice. <i>Scientific Reports</i> , 2019, 9, 16024.	3.3	4
113	ANALYSIS OF FLUID IN CAPSULES IMPLANTED INTO DOG BRAIN. <i>The Japanese Journal of Physiology</i> , 1974, 24, 59-71.	0.9	4
114	FIBRINOLYTIC ACTIVITY IN LIVER TISSUES OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995, 22, S275-S276.	1.9	3
115	Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells. <i>Thrombosis Research</i> , 2004, 113, 41-49.	1.7	3
116	The Absence of Urokinase-type Plasminogen Activator Receptor Plays a Role in the Insulin-independent Glucose Metabolism. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 334-339.	1.9	3
117	Spatiotemporal differences in vascular permeability after ischaemic brain damage. <i>NeuroReport</i> , 2011, 22, 424-427.	1.2	3
118	Tissue plasminogen activator deficiency promotes early phase regeneration in the olfactory epithelium after bulbectomy. <i>International Forum of Allergy and Rhinology</i> , 2013, 3, 458-467.	2.8	3
119	Plasminogen activator inhibitor-1 is involved in interleukin-1 β -induced matrix metalloproteinase expression in murine chondrocytes. <i>Modern Rheumatology</i> , 2019, 29, 959-963.	1.8	3
120	New Aspects of Fibrinolytic Proteins in Brain Development.. <i>Cell Structure and Function</i> , 1997, 22, 225-229.	1.1	3
121	Role of Macrophages and Plasminogen Activator Inhibitor-1 in Delayed Bone Repair Induced by Glucocorticoids in Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 478.	4.1	3
122	Alpha2-antiplasmin deficiency affects depression and anxiety-like behavior and apoptosis induced by stress in mice. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, .	1.3	3
123	Absence of t-PA in spontaneous metastatic lesions induced by a newly established cell line. <i>Thrombosis Research</i> , 1989, 53, 395-400.	1.7	2
124	Secretion of Plasminogen Activator in Response to Follicle-Stimulating Hormone in Culture Medium of Human Testicular Cells from Biopsy Specimens. <i>Journal of Andrology</i> , 1989, 10, 283-288.	2.0	2
125	Effect of clinical clerkship on students' attitudes toward medical learning in Japan: a case study at Kinki University School of Medicine. <i>Pathophysiology</i> , 2003, 9, 111-113.	2.2	2
126	Mechanism of the experimental antithrombotic effect of some apple varieties involves enhanced endogenous thrombolytic activity. <i>Interventional Medicine & Applied Science</i> , 2012, 4, 115-124.	0.2	2

#	ARTICLE	IF	CITATIONS
127	A synthetic peptide derived from staphylokinase enhances FGF-2-induced skin wound healing in mice. <i>Thrombosis Research</i> , 2017, 157, 7-8.	1.7	2
128	Î±2-Antiplasmin as a potential regulator of the spatial memory process and age-related cognitive decline. <i>Molecular Brain</i> , 2020, 13, 140.	2.6	2
129	Effect of monensin on secretion of t-PA from melanoma (Bowes).. <i>Cell Structure and Function</i> , 1989, 14, 673-684.	1.1	2
130	Regulation of scu-PA secretion and u-PA Receptor Expression in Osteoblast-like Cells.. <i>Cell Structure and Function</i> , 1993, 18, 355-362.	1.1	2
131	Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo. <i>Thrombosis and Haemostasis</i> , 2002, 87, 1069-74.	3.4	2
132	Fibrinolytic factors, matrix metalloproteinase-1, and tissue inhibitor of metalloproteinase-1 in gastric carcinoma. <i>Pathophysiology</i> , 1998, 5, 99-104.	2.2	1
133	Binding of mutant tissue-type plasminogen activators to human endothelial cells and their extracellular matrix. <i>Life Sciences</i> , 2000, 66, 2473-2487.	4.3	1
134	Role of Fibrinolysis in Hepatic Regeneration. , 2008, , 336-347.		1
135	Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function.. <i>Journal of Biological Chemistry</i> , 2014, 289, 15154.	3.4	1
136	Enhanced pre-operative thrombolytic status is associated with the incidence of deep venous thrombosis in patients undergoing total knee arthroplasty. <i>Thrombosis Journal</i> , 2014, 12, 11.	2.1	1
137	Role of plasminogen activator inhibitor-1 in muscle wasting induced by a diabetic state in female mice. <i>Endocrine Journal</i> , 2021, 68, 1421-1428.	1.6	1
138	Localization of Factor VIII Interactive Site within Plasmin/Plasminogen Which Is Responsible for Plasmin-Catalyzed Activation/Inactivation of Factor VIII.. <i>Blood</i> , 2007, 110, 1759-1759.	1.4	1
139	Comparative Studies of Thrombolysis with Single-Chain and Two-Chain Recombinant Tissue-Type Plasminogen Activators in Canine Coronary Thrombosis. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 28, 571-575.	1.9	1
140	Determination of the biological activity of antithrombin III related antigen in urine. <i>Clinica Chimica Acta</i> , 1989, 180, 79-86.	1.1	0
141	Influence of Low- and High-Molecular-Weight Plasminogen Activators on the Onset of Labor and on the Hemostatic System. <i>Seminars in Thrombosis and Hemostasis</i> , 2002, 28, 529-532.	2.7	0
142	Enhancement of fibrinolytic activity in vascular endothelial cells by heterologous expression of adenine nucleotide translocase-1. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 272-278.	1.0	0
143	Pathophysiology in Japan. <i>Pathophysiology</i> , 2010, 17, 71.	2.2	0
144	Liver regeneration and fibrinolytic system. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2008, 19, 216-225.	0.1	0

#	ARTICLE	IF	CITATIONS
145	Turning point on the development of research career. Japanese Journal of Thrombosis and Hemostasis, 2012, 23, 520-526.	0.1	0
146	Properties of granuloma associated plasminogen activator (PA) and its relation to macrophage PA.. Blood & Vessel, 1985, 16, 220-222.	0.0	0
147	Role of plasmionogen activator inhibitor-1 in the pathogenesis of bone metabolism abnormalities. Japanese Journal of Thrombosis and Hemostasis, 2015, 26, 619-625.	0.1	0